Sientra (NASDAQ:SIEN) Announces Earnings Results, Misses Expectations By $0.50 EPS

Sientra (NASDAQ:SIEN) announced its earnings results on Thursday. The medical instruments supplier reported ($1.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.50), Briefing.com reports. Sientra had a negative return on equity of 119.59% and a negative net margin of 126.32%. The firm had revenue of $20.53 million for the quarter, compared to analyst estimates of $19.04 million. During the same quarter last year, the business posted ($0.73) EPS. The firm’s revenue was up 17.0% compared to the same quarter last year. Sientra updated its FY 2019 guidance to EPS.

Shares of SIEN traded up $1.40 during mid-day trading on Friday, reaching $6.39. The company had a trading volume of 5,799,098 shares, compared to its average volume of 1,027,938. The firm has a market capitalization of $151.63 million, a PE ratio of -1.97 and a beta of 0.29. The company’s fifty day simple moving average is $5.88. Sientra has a fifty-two week low of $4.78 and a fifty-two week high of $26.65. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.16 and a current ratio of 1.52.

In related news, Director Keith J. Sullivan purchased 20,869 shares of the firm’s stock in a transaction on Friday, June 7th. The shares were bought at an average price of $5.75 per share, for a total transaction of $119,996.75. Following the acquisition, the director now directly owns 203,141 shares in the company, valued at $1,168,060.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Paul Sean Little purchased 17,391 shares of the firm’s stock in a transaction on Friday, June 7th. The stock was bought at an average price of $5.75 per share, for a total transaction of $99,998.25. Following the acquisition, the chief financial officer now owns 94,891 shares in the company, valued at $545,623.25. The disclosure for this purchase can be found here. 13.30% of the stock is owned by company insiders.

A number of brokerages recently issued reports on SIEN. Canaccord Genuity raised their target price on shares of Sientra from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Friday. ValuEngine upgraded shares of Sientra from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Wells Fargo & Co upgraded shares of Sientra from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $8.00 to $10.00 in a research report on Wednesday, June 5th. Zacks Investment Research upgraded shares of Sientra from a “sell” rating to a “hold” rating in a report on Wednesday, April 17th. Finally, Craig Hallum decreased their price target on shares of Sientra from $20.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, July 25th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $15.71.

About Sientra

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Featured Story: Strike Price

Earnings History for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.